Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-253 in Advanced Solid Tumors
NCT07807956Phase 1Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABBV-253 in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 6 more (4 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants With Adverse Events at 4 years, Number of Participants with Abnormal Change from Baseline in Clinical Laboratory Test Results at 4 years and 3 more. Started Sep 2026; status: recruiting.
02
Drugs
ABBV-253
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)gastric cancer (GC)
Beyond the preview
Go deeper on NCT07807956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07807956.